Managing Symptom Profile of IBS-D Patients With Tritordeum-Based Foods: Results From a Pilot Study

Francesco Russo, Giuseppe Riezzo, Michele Linsalata, Antonella Orlando, Valeria Tutino, Laura Prospero, Benedetta D'Attoma, Gianluigi Giannelli, Francesco Russo, Giuseppe Riezzo, Michele Linsalata, Antonella Orlando, Valeria Tutino, Laura Prospero, Benedetta D'Attoma, Gianluigi Giannelli

Abstract

In the past few years, increasing attention has been given to the pathologic role of specific foods in IBS, like wheat and other cereals. Recent literature describes IBS patients who may experience gastrointestinal (GI) and extra-GI symptoms precipitated by the ingestion of cereals. Tritordeum is a cereal of Spanish origin derived from the hybridization of durum wheat and wild barley. It is different from classic wheat for its gluten protein composition, with fewer carbohydrates and fructans and a higher content of proteins, dietary fibers, and antioxidants. This pilot study aimed to investigate the effects of a 12-week diet with Tritordeum-based foods in substitution of other cereals on the profile of GI symptoms (evaluated by appropriate questionnaire) and the health of the GI barrier (assessed by sugar absorption test and different markers of integrity and functions) in 16 diarrhea-predominant IBS (IBS-D) patients. The diet with Tritordeum-based foods (bread, bakery products, and pasta) significantly reduced IBS-D patients' symptoms. This amelioration appears to occur through an overall improvement of the GI barrier, as demonstrated by the reduced intestinal permeability and the decreased levels of markers of intestinal mucosal integrity, mucosal inflammation, and fermentative dysbiosis.

Keywords: Tritordeum; diet; dysbiosis; gastrointestinal symptoms; inflammation; intestinal permeability; irritable bowel syndrome.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Russo, Riezzo, Linsalata, Orlando, Tutino, Prospero, D'Attoma and Giannelli.

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
The flow of the patients through the study.
Figure 3
Figure 3
Small intestinal permeability as evaluated by the sugar absorption test in urine [A = % lactulose (La); B = % mannitol (Ma); C = La/Ma ratio; D = % sucrose (Su)] before (pre) and after (post) 12 weeks of Tritordeum-based diet in 16 IBS-D patients. Data expressed as means ± SEM. Wilcoxon rank-sum test was used to compare pre- and post-treatment data. Differences were considered significant at P < 0.05. Dotted line indicates the cut-off values for the La/Ma ratio. A La/Ma ratio higher than 0.03 represented altered s-IP.
Figure 4
Figure 4
Biomarkers of intestinal barrier function and integrity (A = fecal zonulin; B = serum zonulin; C = serum intestinal fatty acid-binding protein—I-FABP; D = serum diamine oxidase—DAO) before (pre) and after (post) 12 weeks of Tritordeum-based diet in 16 IBS-D patients. Data expressed as means ± SEM. Wilcoxon rank-sum test was used to compare pre- and post-treatment data. Differences were considered significant at P < 0.05. Dotted line indicates the cut-off values for fecal and serum zonulin. Normal fecal and serum zonulin concentrations have to be below 107 and 48 ng/mL, respectively.
Figure 5
Figure 5
Urinary indican (A), urinary skatole (B), and serum lipopolysaccharide (LPS) (C) levels before (pre) and after (post) 12 weeks of Tritordeum-based diet in 16 IBS-D patients. Data expressed as means ± SEM. Wilcoxon rank-sum test was used to compare pre- and post-treatment data. Differences considered significant at P < 0.05. Dotted line indicates the grade I dysbiosis for indican (20 mg/L) and skatole (20 μg/L), respectively.

References

    1. Chey WD, Olden K, Carter E, Boyle J, Drossman D, Chang L. Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women. Am J Gastroenterol. (2002) 97:2803–11. 10.1111/j.1572-0241.2002.07026.x
    1. Schmulson MJ, Drossman DA. What is new in Rome IV. J NeurogastroenterolMotil. (2017) 23:151–63. 10.5056/jnm16214
    1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. (2006) 130:1480–91. 10.1053/j.gastro.2005.11.061
    1. Tuck CJ, Reed DE, Muir JG, Vanner SJ. Implementation of the low FODMAP diet in functional gastrointestinal symptoms: a real-world experience. NeurogastroenterolMotil. (2020) 32:e13730. 10.1111/nmo.13730
    1. Linsalata M, Riezzo G, Orlando A, D'attoma B, Prospero L, Tutino V, et al. . The relationship between low serum vitamin D levels and altered intestinal barrier function in patients with IBS diarrhoea undergoing a long-term low-FODMAP diet: novel observations from a clinical trial. Nutrients. (2021) 13:1011. 10.3390/nu13031011
    1. Orlando A, Tutino V, Notarnicola M, Riezzo G, Linsalata M, Clemente C, et al. . Improved symptom profiles and minimal inflammation in IBS-D patients undergoing a long-term low-FODMAP diet: a lipidomic perspective. Nutrients. (2020) 12:1652. 10.3390/nu12061652
    1. RotondiAufiero V, Fasano A, Mazzarella G. Non-celiac gluten sensitivity: how its gut immune activation and potential dietary management differ from celiac disease. Mol Nutr Food Res. (2018) 62:e1700854. 10.1002/mnfr.201700854
    1. Barmeyer C, Schumann M, Meyer T, Zielinski C, Zuberbier T, Siegmund B, et al. . Long-term response to gluten-free diet as evidence for non-celiac wheat sensitivity in one third of patients with diarrhea-dominant and mixed-type irritable bowel syndrome. Int J Colorectal Dis. (2017) 32:29–39. 10.1007/s00384-016-2663-x
    1. Aziz I, Trott N, Briggs R, North JR, Hadjivassiliou M, Sanders DS. Efficacy of a gluten- free diet in subjects with irritable bowel syndrome-diarrhea unaware of their HLA-DQ2/8 genotype. Clin Gastroenterol Hepatol. (2016) 14:696–703.e1. 10.1016/j.cgh.2015.12.031
    1. Martín A, Alvarez JB, Martín LM, Barro F, Ballesteros J. The development of tritordeum: a novel cereal for food processing. J Cereal Sci. (1999) 30:85–95. 10.1006/jcrs.1998.0235
    1. Vaquero L, Comino I, Vivas S, Rodriguez-Martin L, Gimenez MJ, Pastor J, et al. . Tritordeum: a novel cereal for food processing with good acceptability and significant reduction in gluten immunogenic peptides in comparison with wheat. J Sci Food Agric. (2018) 98:2201–9. 10.1002/jsfa.8705
    1. Sanchez-Leon S, Haro C, Villatoro M, Vaquero L, Comino I, Gonzalez-Amigo AB, et al. . Tritordeum breads are well tolerated with preference over gluten-free breads in non-celiac wheat-sensitive patients and its consumption induce changes in gut bacteria. J Sci Food Agric. (2020) 101:3508–17.10.1002/jsfa.10982
    1. Cardoso-Silva D, Delbue D, Itzlinger A, Moerkens R, Withoff S, Branchi F, et al. . Intestinal barrier function in gluten-related disorders. Nutrients. (2019) 11:2325. 10.3390/nu11102325
    1. Linsalata M, Riezzo G, D'attoma B, Clemente C, Orlando A, Russo F. Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: a case-control study. BMC Gastroenterol. (2018) 18:167. 10.1186/s12876-018-0888-6
    1. Linsalata M, Riezzo G, Clemente C, D'attoma B, Russo F. Noninvasive biomarkers of gut barrier function in patients suffering from diarrhea predominant-IBS: an update. Dis Markers. (2020) 2020:2886268. 10.1155/2020/2886268
    1. Camilleri M . Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. (2019) 68:1516–26. 10.1136/gutjnl-2019-318427
    1. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. (2011) 91:151–75. 10.1152/physrev.00003.2008
    1. Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta. (2005) 352:15–35. 10.1016/j.cccn.2004.09.001
    1. Song WB, Lv YH, Zhang ZS, Li YN, Xiao LP, Yu XP, et al. . Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease. World J Gastroenterol. (2009) 15:3916–9. 10.3748/wjg.15.3916
    1. Zhang L, Fan X, Zhong Z, Xu G, Shen J. Association of plasma diamine oxidase and intestinal fatty acid-binding protein with severity of disease in patient with heat stroke. Am J Emerg Med. (2015) 33:867–71. 10.1016/j.ajem.2015.01.047
    1. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. (1997) 11:395–402. 10.1046/j.1365-2036.1997.142318000.x
    1. Verdu EF, Armstrong D, Murray JA. Between celiac disease and irritable bowel syndrome: the no man's land of gluten sensitivity. Am J Gastroenterol. (2009) 104:1587–94. 10.1038/ajg.2009.188
    1. Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment PharmacolTher. (2016) 44:693–703. 10.1111/apt.13746
    1. Maagaard L, Ankersen DV, Vegh Z, Burisch J, Jensen L, Pedersen N, et al. . Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet. World J Gastroenterol. (2016) 22:4009–19. 10.3748/wjg.v22.i15.4009
    1. Linsalata M, D'attoma B, Orlando A, Guerra V, Russo F. Comparison of an enzymatic assay with liquid chromatography-pulsed amperometric detection for the determination of lactulose and mannitol in urine of healthy subjects and patients with active celiac disease. Clin Chem Lab Med. (2014) 52:e61–4. 10.1515/cclm-2013-0468
    1. Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology. (1996) 110:1395–403. 10.1053/gast.1996.v110.pm8613043
    1. Simeoni M, Citraro ML, Cerantonio A, Deodato F, Provenzano M, Cianfrone P, et al. . An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD). Eur J Nutr. (2019) 58:2145–56. 10.1007/s00394-018-1785-z
    1. Lombardi F, Fiasca F, Minelli M, Maio D, Mattei A, Vergallo I, et al. . The effects of low-nickel diet combined with oral administration of selected probiotics on patients with systemic nickel allergy syndrome (SNAS) and gut dysbiosis. Nutrients. (2020) 12:1040. 10.3390/nu12041040
    1. Drossman DA, Chang L, Bellamy N, Gallo-Torres HE, Lembo A, Mearin F, et al. . Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Am J Gastroenterol. (2011) 106:1749–59; quiz: 1760. 10.1038/ajg.2011.201
    1. De Giorgio R, Volta U, Gibson PR. Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction? Gut. (2016) 65:169–78. 10.1136/gutjnl-2015-309757
    1. Catassi C, Bai JC, Bonaz B, Bouma G, Calabro A, Carroccio A, et al. . Non-Celiac Gluten sensitivity: the new frontier of gluten related disorders. Nutrients. (2013) 5:3839–53. 10.3390/nu5103839
    1. Dieterich W, Zopf Y. Gluten and FODMAPS-sense of a restriction/when is restriction necessary? Nutrients. (2019) 11:1957. 10.3390/nu11081957
    1. Nilholm C, Larsson E, Roth B, Gustafsson R, Ohlsson B. Irregular dietary habits with a high intake of cereals and sweets are associated with more severe gastrointestinal symptoms in IBS patients. Nutrients. (2019) 11:1279. 10.3390/nu11061279
    1. Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, Törnblom H, et al. . Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. (2015) 149:1399–407.e2. 10.1053/j.gastro.2015.07.054
    1. Haro C, Villatoro M, Vaquero L, Pastor J, Gimenez MJ, Ozuna CV, et al. . The dietary intervention of transgenic low-gliadin wheat bread in patients with non-celiac gluten sensitivity (NCGS) showed no differences with gluten free diet (GFD) but provides better gut microbiota profile. Nutrients. (2018) 10:1964. 10.3390/nu10121964
    1. Schwenk A, Eschner W, Kremer G, Ward LC. Assessment of intracellular water by whole body bioelectrical impedance and total body potassium in HIV-positive patients. Clin Nutr. (2000) 19:109–13. 10.1054/clnu.1999.0078
    1. Stapel SN, Looijaard W, Dekker IM, Girbes ARJ, Weijs PJM, Oudemans-van Straaten HM. Bioelectrical impedance analysis-derived phase angle at admission as a predictor of 90-day mortality in intensive care patients. Eur J Clin Nutr. (2018) 72:1019–25. 10.1038/s41430-018-0167-1
    1. Ghosh SS, Wang J, Yannie PJ, Ghosh S. Intestinal barrier dysfunction, LPS translocation, and disease development. J Endocr Soc. (2020) 4:bvz039. 10.1210/jendso/bvz039
    1. Fritscher-Ravens A, Schuppan D, Ellrichmann M, Schoch S, Rocken C, Brasch J, et al. . Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology. (2014) 147:1012–20. 10.1053/j.gastro.2014.07.046
    1. Wu RL, Vazquez-Roque MI, Carlson P, Burton D, Grover M, Camilleri M, et al. . Gluten-induced symptoms in diarrhea-predominant irritable bowel syndrome are associated with increased myosin light chain kinase activity and claudin-15 expression. Lab Invest. (2017) 97:14–23. 10.1038/labinvest.2016.118
    1. Usai-Satta P, Bassotti G, Bellini M, Oppia F, Lai M, Cabras F. Irritable bowel syndrome and gluten-related disorders. Nutrients. (2020) 12:1117. 10.3390/nu12041117
    1. Elli L, Tomba C, Branchi F, Roncoroni L, Lombardo V, Bardella MT, et al. . Evidence for the presence of non-celiac gluten sensitivity in patients with functional gastrointestinal symptoms: results from a multicenter randomized double-blind placebo-controlled gluten challenge. Nutrients. (2016) 8:84. 10.3390/nu8020084

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner